

Amendments to the Claims:

The listing of claims will replace all prior versions of claims in the application:

Listing of Claims:

1. (cancelled)
2. (Withdrawn) A pharmaceutical composition method for preventing cyclosporin A-induced cytotoxicity by the overexpression of cyclophilin with PPIase activity in transplanted cells, comprising using a cell for use in transplantation in which the cyclophilin protein with peptidyl-prolyl-cis-trans isomerase activity is overexpressed comprising a recombinant expression vector which can express the cyclophilin protein in such a sufficient amount as to in an amount sufficient to reduce the toxicity induced by cyclosporin A or its analogues in transplanted cells.
3. (Withdrawn) The method The pharmaceutical composition as defined in claim 2, wherein the cell for use in transplantation transplanted cells are myoblasts is a myoblast.
4. (cancelled).
5. (cancelled).
6. (Withdrawn) A method of preparing cells for use in the transplantation which are resistant to cyclosporin A or its analogues; The method of claim 2 wherein the cell for use in [[the]] transplantation is prepared by a process comprising the steps of introducing a gene encoding a cyclophilin protein with PPIase peptidyl-prolyl-cis-trans isomerase activity into a vector to construct a recombinant expression vector, transfected the recombinant expression vector into cells to be transplanted, culturing the transfected cells, and selecting cells in which the cyclophilin with PPIase peptidyl-prolyl-cis-trans isomerase activity is over-expressed.
7. (Withdrawn) A method of preparing cells for use in the transplantation which are resistant to cyclosporin A or its analogues; The method of claim 6, wherein the step of culturing the transformed cell is performed [[comprising the steps of culturing cells to be transplanted]] in the presence of cyclosporin A or its analogues and recovering viable cells from the cultures.
8. (Withdrawn) The method as defined in claim [[6]] 7, wherein the eells are myoblasts step of

Selecting a cell in which the cyclophilin with peptidyl-prolyl-cis-trans isomerase activity is overexpressed is preformed by recovering a viable cell from the culture .

9. (cancelled).

10. (New) A pharmaceutical composition for preventing cyclosporin A-induced cytotoxicity by the overexpression of cyclophilin with PPIase activity in a transplanted cell, wherein the transplanted cell is an H0c2 rat cardiac myoblast transfected with a vector expressing a CypA gene.

11. (New) The pharmaceutical composition of claim 10, wherein the CypA gene is mutated so as to express a CypA protein comprising a phenylalanine residue instead of a tryptophan residue at position 121.

12. (New) The pharmaceutical composition of claim 10 wherein the cell is designated as CypA/wt or CypA/W121F.

13. (New) A method of preparing a cell for use in transplantation that is resistant to cyclosporin A or its analogues, comprising the steps of introducing a gene encoding a cyclophilin protein with PPIase activity into a vector to construct a recombinant expression vector, transfecting the recombinant expression vector into an H0c2 rat cardiac myoblast., culturing the transfected H0c2 rat cardiac myoblast, and selecting a cultured H0c2 rat cardiac myoblast in which the cyclophilin with PPIase activity is over- expressed.

14. (New) The method of claim 13 wherein the CypA gene is mutated so as to express a CypA protein comprising a phenylalanine residue instead of a tryptophan residue at position 121.

15. (New) The method of claim 13 wherein the cell is designated as CypA/wt or CypA/W121F.